5 results
The main purpose of this trial is to find out if an investigational drug called setmelanotide (RM-493), which mimics MSH, can help control body weight. The efficacy of setmelanotide will be compared to the efficacy of a placebo during 4 to 8 weeks.
Primary:• To evaluate the proportion of patients with obesity with genetic variants in a specific gene in the melanocortin-4 receptor (MC4R) pathway who achieve a clinically meaningful reduction in body weight in response to setmelanotide at the end…
To assess the superiority of an IVUS-guided approach versus a qualitative angio-guided approach in patients with complex coronary lesions undergoing PCI.
To evaluate the efficacy of setmelanotide on changes in body weight.
The main objective is to investigate whether the additional use of IVUS leads to an increase in net lumen gain (NLG) when compared with standard angiography-guided endovascular treatment as measured during control IVUS after six weeks. Secondary…